Recommendation of pharmacokinetics/pharmacodynamics target of ethambutol to suppress tuberculosis resistance: A population pharmacokinetics study on a large prospective cohort
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS62(2) · 2023
- 피인용
- Web of Science 4Scopus 3
- FWCI (Scopus)
- 0.34
- JCR IF
- JCR 2022 10.8
- ISSN
- 0924-8579
저자
- Hung, Tran Minh제1저자bDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
- Jayanti, Rannissa PuspitabDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
- Lee, Ho YoungbDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
- Kim, Hyo JungbDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
- 목정하eDepartment of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea
- Jang, Tae WonfPulmonary Division, Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Republic of Korea
- Oh, Jee YoungDivision of Pulmonology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea
- Kim, Ju SanghDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
- Ko, YousangiDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Seoul, Republic of Korea
- Min, JinsoohDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
- Hoa, Pham QuangbDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
- Ahn, SangzinbDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
- Long, Nguyen PhuocbDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
- Cho, Yong Soon교신저자bDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
- Shin, Jae Gook교신저자bDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
초록
Background: The ability of ethambutol (EMB) to suppress bacterial resistance has been demonstrated in a time-dependent manner. Through the development of a population pharmacokinetics (PK) model, this study aimed to suggest the PK/pharmacodynamics (PD) target and identify the significant covariates that influence interindividual variability (IIV) in the PK of EMB. Methods: In total, 837 patients from 20 medical centres across Korea were enrolled in this study. The non-linear mixed-effect method was used to establish and validate the population PK model. Results: A two-compartment model with transit compartment absorption was sufficient to describe the PK of EMB. Body weight and renal function were identified as significant covariates that affect IIV of the apparent clearance (CL/F) of EMB. Patients with moderate renal function showed 35% and 55% lower CL/F (CL/F 89.9 L/h) compared with those with mild and normal renal function, respectively. All the renal function groups with simulated doses ranging from 800 to 1200 mg achieved area under the curve over minimum inhibitory concentration (MIC) >119, and maintained T>MIC for >23 h for MIC of 0.5 µg/mL. Based on our simulation result, it is suggested that doses of 800, 1000, and 1200 mg should obtain the T>MIC target of 4, 6, and 8 h, respectively. This model was validated internally and externally. Conclusion: This study provides insight into the PK/PD indexes of EMB for three different renal function groups and T>MIC targets for different doses. The results could be used to provide optimal-dose suggestions for EMB.
키워드
EthambutolPharmacokinetics/pharmacodynamics targetPopulation pharmacokineticsTherapeutic drug monitoringTuberculosisANTITUBERCULOSIS DRUGSBREAKPOINTSKINETICSIMPACTFOODMASS
식별자
- Scopus EID
- 2-s2.0-85162156964
- WoS UID
- 001024526000001



로그인
연구물 목록으로